Life Diagnostics, Inc. adds two new alpha-fetoprotein (AFP) assays to its extensive lineup of SPARCL assays. The new assays were developed for cats (AFP-SP-8) and dogs (AFP-SP-4).
Serum alpha-fetoprotein (AFP) levels are elevated in humans and dogs suffering from liver cancer, liver disease and some non-hepatic cancers, allowing AFP to be used as a biomarker to monitor disease progression.
- Life Diagnostics researchers found levels as high as 500 ng/ml in serum of cats with cancer. Levels in serum from healthy cats were undetectable.
- Serum alpha-fetoprotein (AFP) levels are elevated in dogs suffering from liver cancer, liver disease and some non-hepatic cancers. Levels decrease after surgical removal of tumors and during cancer remission.
In addition to fully developed and tested SPARCL assay kits, Life Diagnostics provides HRP and acridan conjugation services for the development of new SPARCL assays. Please visit the Life Diagnostics SPARCL Assay web page for more information.
